Predictive assay for cancer targets

Amanda Suess, Christine Nguyen, Karen Sorensen, Jennifer Montgomery, Brian Souza, Kris Kulp, Larry Dugan, Allen Christian

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Early detection of cancer is a key element in successful treatment of the disease. Understanding the particular type of cancer involved, its origins and probable course, is also important. PhIP (2-amino-1-methyl-6 phenylimidazo [4,5-b]pyridine), a heterocyclic amine produced during the cooking of meat at elevated temperatures, has been shown to induce mammary cancer in female, Sprague-Dawley rats. Tumors induced by PhIP have been shown to contain discreet cytogenetic signature patterns of gains and losses using comparative genomic hybridization (CGH). To determine if a protein signature exists for these tumors, we are analyzing expression levels of the protein products of the abovementioned tumors in combination with a new bulk protein subtractive assay. This assay produces a panel of antibodies against proteins that are either on or off in the tumor. Hybridization of the antibody panel onto a 2-D gel of tumor or control protein will allow for identification of a distinct protein signature in. the tumor. Analysis of several gene databases has identified a number of rat homologs of human cancer genes located in these regions of gain and loss. These genes include the oncogenes c-MYK, ERBB2/NEU, THRA and tumor suppressor genes EGR1 and HDAC3. The listed genes have been shown to be estrogen-responsive, suggesting a possible link between delivery of bio-activated PhIP to the cell nucleus via estrogen receptors and gene-specific PhIP-induced DNA damage, leading to cell transformation. All three tumors showed similar silver staining patterns compared to each other, while they all were different than the control tissue. Subsequent screening of these genes against those from tumors know to be caused by other agents may produce a protein signature unique to PhIP, which can be used as a diagnostic to augment optical and radiation-based detection schemes.

Original languageEnglish (US)
Title of host publicationProceedings of SPIE - The International Society for Optical Engineering
EditorsB.M. Cullum, J.C. Carter
Volume6007
DOIs
StatePublished - 2005
Externally publishedYes
EventSmart Medical and Biomedical Sensor Technology III - Boston, MA, United States
Duration: Oct 24 2005Oct 26 2005

Other

OtherSmart Medical and Biomedical Sensor Technology III
CountryUnited States
CityBoston, MA
Period10/24/0510/26/05

Fingerprint

Tumors
Assays
tumors
cancer
Genes
genes
proteins
Proteins
signatures
oncogenes
estrogens
antibodies
rats
Antibodies
Rats
tumor suppressor genes
staining
Meats
Cooking
Pyridine

Keywords

  • Biomarkers
  • Laser Capture Microdissection
  • MALDI-TOF
  • Mass Spectrometry
  • Microarray
  • Peptide
  • Proteomics
  • SELDI-TOF
  • Serum
  • Transcript

ASJC Scopus subject areas

  • Electrical and Electronic Engineering
  • Condensed Matter Physics

Cite this

Suess, A., Nguyen, C., Sorensen, K., Montgomery, J., Souza, B., Kulp, K., ... Christian, A. (2005). Predictive assay for cancer targets. In B. M. Cullum, & J. C. Carter (Eds.), Proceedings of SPIE - The International Society for Optical Engineering (Vol. 6007). [600715] https://doi.org/10.1117/12.630804

Predictive assay for cancer targets. / Suess, Amanda; Nguyen, Christine; Sorensen, Karen; Montgomery, Jennifer; Souza, Brian; Kulp, Kris; Dugan, Larry; Christian, Allen.

Proceedings of SPIE - The International Society for Optical Engineering. ed. / B.M. Cullum; J.C. Carter. Vol. 6007 2005. 600715.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Suess, A, Nguyen, C, Sorensen, K, Montgomery, J, Souza, B, Kulp, K, Dugan, L & Christian, A 2005, Predictive assay for cancer targets. in BM Cullum & JC Carter (eds), Proceedings of SPIE - The International Society for Optical Engineering. vol. 6007, 600715, Smart Medical and Biomedical Sensor Technology III, Boston, MA, United States, 10/24/05. https://doi.org/10.1117/12.630804
Suess A, Nguyen C, Sorensen K, Montgomery J, Souza B, Kulp K et al. Predictive assay for cancer targets. In Cullum BM, Carter JC, editors, Proceedings of SPIE - The International Society for Optical Engineering. Vol. 6007. 2005. 600715 https://doi.org/10.1117/12.630804
Suess, Amanda ; Nguyen, Christine ; Sorensen, Karen ; Montgomery, Jennifer ; Souza, Brian ; Kulp, Kris ; Dugan, Larry ; Christian, Allen. / Predictive assay for cancer targets. Proceedings of SPIE - The International Society for Optical Engineering. editor / B.M. Cullum ; J.C. Carter. Vol. 6007 2005.
@inproceedings{29ed427a81704cad9e7ae5a1201b7990,
title = "Predictive assay for cancer targets",
abstract = "Early detection of cancer is a key element in successful treatment of the disease. Understanding the particular type of cancer involved, its origins and probable course, is also important. PhIP (2-amino-1-methyl-6 phenylimidazo [4,5-b]pyridine), a heterocyclic amine produced during the cooking of meat at elevated temperatures, has been shown to induce mammary cancer in female, Sprague-Dawley rats. Tumors induced by PhIP have been shown to contain discreet cytogenetic signature patterns of gains and losses using comparative genomic hybridization (CGH). To determine if a protein signature exists for these tumors, we are analyzing expression levels of the protein products of the abovementioned tumors in combination with a new bulk protein subtractive assay. This assay produces a panel of antibodies against proteins that are either on or off in the tumor. Hybridization of the antibody panel onto a 2-D gel of tumor or control protein will allow for identification of a distinct protein signature in. the tumor. Analysis of several gene databases has identified a number of rat homologs of human cancer genes located in these regions of gain and loss. These genes include the oncogenes c-MYK, ERBB2/NEU, THRA and tumor suppressor genes EGR1 and HDAC3. The listed genes have been shown to be estrogen-responsive, suggesting a possible link between delivery of bio-activated PhIP to the cell nucleus via estrogen receptors and gene-specific PhIP-induced DNA damage, leading to cell transformation. All three tumors showed similar silver staining patterns compared to each other, while they all were different than the control tissue. Subsequent screening of these genes against those from tumors know to be caused by other agents may produce a protein signature unique to PhIP, which can be used as a diagnostic to augment optical and radiation-based detection schemes.",
keywords = "Biomarkers, Laser Capture Microdissection, MALDI-TOF, Mass Spectrometry, Microarray, Peptide, Proteomics, SELDI-TOF, Serum, Transcript",
author = "Amanda Suess and Christine Nguyen and Karen Sorensen and Jennifer Montgomery and Brian Souza and Kris Kulp and Larry Dugan and Allen Christian",
year = "2005",
doi = "10.1117/12.630804",
language = "English (US)",
volume = "6007",
editor = "B.M. Cullum and J.C. Carter",
booktitle = "Proceedings of SPIE - The International Society for Optical Engineering",

}

TY - GEN

T1 - Predictive assay for cancer targets

AU - Suess, Amanda

AU - Nguyen, Christine

AU - Sorensen, Karen

AU - Montgomery, Jennifer

AU - Souza, Brian

AU - Kulp, Kris

AU - Dugan, Larry

AU - Christian, Allen

PY - 2005

Y1 - 2005

N2 - Early detection of cancer is a key element in successful treatment of the disease. Understanding the particular type of cancer involved, its origins and probable course, is also important. PhIP (2-amino-1-methyl-6 phenylimidazo [4,5-b]pyridine), a heterocyclic amine produced during the cooking of meat at elevated temperatures, has been shown to induce mammary cancer in female, Sprague-Dawley rats. Tumors induced by PhIP have been shown to contain discreet cytogenetic signature patterns of gains and losses using comparative genomic hybridization (CGH). To determine if a protein signature exists for these tumors, we are analyzing expression levels of the protein products of the abovementioned tumors in combination with a new bulk protein subtractive assay. This assay produces a panel of antibodies against proteins that are either on or off in the tumor. Hybridization of the antibody panel onto a 2-D gel of tumor or control protein will allow for identification of a distinct protein signature in. the tumor. Analysis of several gene databases has identified a number of rat homologs of human cancer genes located in these regions of gain and loss. These genes include the oncogenes c-MYK, ERBB2/NEU, THRA and tumor suppressor genes EGR1 and HDAC3. The listed genes have been shown to be estrogen-responsive, suggesting a possible link between delivery of bio-activated PhIP to the cell nucleus via estrogen receptors and gene-specific PhIP-induced DNA damage, leading to cell transformation. All three tumors showed similar silver staining patterns compared to each other, while they all were different than the control tissue. Subsequent screening of these genes against those from tumors know to be caused by other agents may produce a protein signature unique to PhIP, which can be used as a diagnostic to augment optical and radiation-based detection schemes.

AB - Early detection of cancer is a key element in successful treatment of the disease. Understanding the particular type of cancer involved, its origins and probable course, is also important. PhIP (2-amino-1-methyl-6 phenylimidazo [4,5-b]pyridine), a heterocyclic amine produced during the cooking of meat at elevated temperatures, has been shown to induce mammary cancer in female, Sprague-Dawley rats. Tumors induced by PhIP have been shown to contain discreet cytogenetic signature patterns of gains and losses using comparative genomic hybridization (CGH). To determine if a protein signature exists for these tumors, we are analyzing expression levels of the protein products of the abovementioned tumors in combination with a new bulk protein subtractive assay. This assay produces a panel of antibodies against proteins that are either on or off in the tumor. Hybridization of the antibody panel onto a 2-D gel of tumor or control protein will allow for identification of a distinct protein signature in. the tumor. Analysis of several gene databases has identified a number of rat homologs of human cancer genes located in these regions of gain and loss. These genes include the oncogenes c-MYK, ERBB2/NEU, THRA and tumor suppressor genes EGR1 and HDAC3. The listed genes have been shown to be estrogen-responsive, suggesting a possible link between delivery of bio-activated PhIP to the cell nucleus via estrogen receptors and gene-specific PhIP-induced DNA damage, leading to cell transformation. All three tumors showed similar silver staining patterns compared to each other, while they all were different than the control tissue. Subsequent screening of these genes against those from tumors know to be caused by other agents may produce a protein signature unique to PhIP, which can be used as a diagnostic to augment optical and radiation-based detection schemes.

KW - Biomarkers

KW - Laser Capture Microdissection

KW - MALDI-TOF

KW - Mass Spectrometry

KW - Microarray

KW - Peptide

KW - Proteomics

KW - SELDI-TOF

KW - Serum

KW - Transcript

UR - http://www.scopus.com/inward/record.url?scp=33644683218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644683218&partnerID=8YFLogxK

U2 - 10.1117/12.630804

DO - 10.1117/12.630804

M3 - Conference contribution

AN - SCOPUS:33644683218

VL - 6007

BT - Proceedings of SPIE - The International Society for Optical Engineering

A2 - Cullum, B.M.

A2 - Carter, J.C.

ER -